
Quick Links
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
                                    Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa | 
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa | 
|---|---|---|---|---|---|---|
如获批上市,这种试验性治疗将为晚期胃癌和胃食管癌患者提供新的治疗选择...
日本厚生劳动省评估zolbetuximab作为晚期胃癌和胃食管交界处癌患者的治疗方案...
MORPHO III期试验数据入选2023年欧洲血液学协会(EHA)新闻简报,在线上+线下大会上进行口头报告...
经IRC评估的接受EV单药治疗的中国患者客观缓解率(ORR)达到37.5% 北京,2023年6月2日...
Read more about 安斯泰来在2023 ASCO公布Enfortumab Vedotin中国桥接试验积极结果
蛋白质在人体中以不同方式发挥作用,对疾病相关蛋白质进行修饰是制药公司开发有效药物的一项主要战略。虽然许多药物是通过化学合成生产的,
